Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports

Sabino De Placido, Pasquale Rescigno, Piera Federico, Carlo Buonerba, Davide Bosso, Livio Puglia, Michela Izzo, Tania Policastro, Giuseppe Di Lorenzo

Pasquale Rescigno, Piera Federico, Carlo Buonerba, Davide Bosso, Livio Puglia, Michela Izzo, Tania Policastro, Sabino De Placido, Giuseppe Di Lorenzo, Genitourinary Cancer Section, Medical Oncology, Department of Clinical Medicine, Federico II University, Napoli 80140, Italy

Author contributions: De Placido S and Rescigno P contributed to the drafting of the manuscript; Federico P, Buonerba C, Bosso D, Puglia L, Izzo M and Policastro T contributed to the acquisition of the data; De Placido S and Di Lorenzo G contributed to the critical revision of the manuscript.

Correspondence to: Giuseppe Di Lorenzo, MD, PhD, Genitourinary Cancer Section, Medical Oncology, Department of Clinical Medicine, Federico II University, Corso Umberto I, Napoli 80140, Italy. giuseppedilorenzoncol@hotmail.com

Telephone: +39-081-7463660 Fax: +39-081-2203147 Received: January 5, 2014 Revised: March 31, 2014 Accepted: May 8, 2014 Published online: June 16, 2014

Abstract

Prostate cancer is the most common non-cutaneous malignancy for men. The skeleton is the most common metastatic site but, following an improvement in survival, metastases in uncommon sites are being found more frequently in clinical practice, especially brain metastases. Despite the new drugs now available for metastatic castration resistant prostate cancer, no clinical evidence exists about their effectiveness on brain metastases. We describe the clinical history of 3 patients treated with cabazitaxel plus whole brain radiotherapy. These case reports demonstrate that cabazitaxel is highly active and well tolerated in brain metastases.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Cabazitaxel; Brain metastases; Prostate cancer

Core tip: Due to the improvement in terms of survival, the incidence of brain metastases (BMs) has increased in patients with metastatic castration resistant prostate cancer (mCRCP). Despite the large number of treatments now available, the prognosis of patients with BMs is still poor. First, we demonstrate the efficacy of cabazitaxel on brain metastases in three CRPC patients and then show its profile of tolerability in combination with whole brain radiotherapy.

INTRODUCTION

Prostate cancer (PC) is the most common non-cutaneous malignancy for men, with an estimated number of new cases of 241740 in 2013 in the United States[1]. Nevertheless, PC is not the leading cause of death in the male population due to its ability to rarely metastasize to organs other than bones[2].

Although the skeleton remains the most common metastatic site, the availability of new active drugs for metastatic castration resistant prostatic cancer (mCRPC) has changed the natural history of this disease, leading to a considerable improvement in survival so that metastases in previously considered uncommon sites are now found more frequently[3].

Brain is the site of metastases in almost 12% of cases with a poor prognosis at their appearance[4].

Despite an increased incidence of BMs, the impact of new drugs for mCRPC on this metastatic site remains poorly understood. First of all, patients with BMs are not routinely enrolled in phase III clinical trials and there are
no prospective and ad-hoc studies in this particular setting. Actually, there is only preclinical data showing that cabazitaxel is able to pass the brain-blood barrier (BBB)\(^5\) but no evidence about its efficacy in humans.

Otherwise, there is also little data concerning the role of radiation therapy on the treatment of BMs from PC which seems to have only a palliative intent\(^6\). Here, we describe three case reports of brain metastases in CRPC patients who were treated with cabazitaxel plus whole brain radiotherapy.

### CASE REPORT

The patients were 70, 70 and 72 years old. All patients presented at diagnosis with a high risk disease (Table 1). Patients 1 and 2 did not receive primary treatment because bone metastases and lymph node metastases were detected with bone and computed tomography scans. These 2 patients began hormonal therapy with luteinizing hormone releasing hormone analogue (aLHRH) first and then with complete androgen blockage (CAB), adding bicalutamide 50 mg.

Patient 3 underwent prostatectomy and radiotherapy for locally advanced disease. The disease progressed after 5 mo due to the appearance of bone metastases and aLHRH was started. All patients had a long androgen deprivation therapy (ADT) history (36-50 mo). Docetaxel was first line chemotherapy with a progression free survival (PFS) of 7, 7 and 11 mo respectively (Table 1). Patient 3 was treated with abiraterone as second line treatment and progressed after 6 mo.

The patients presented with multiple BMs (in number, 2, 3 and 3 respectively) confirmed with a magnetic resonance imagining (MRI) before starting cabazitaxel and the liver and lung were the other metastatic sites (Table 1). A total of 30 cycles of cabazitaxel were administered at standard dose without reductions (Table 1). Contemporaneous whole brain radiotherapy was performed at the dose of 30 Gy.

Patient 3 obtained a complete response on brain and liver metastases with a PSA reduction of 90% after 6 cycles (Figure 1), while two partial responses in brain (the lesions were halved) and lung were observed, with a PSA decrease of 40% after 6 cycles for patient 1 and 2.

No grade 3-4 toxicities were experienced; all patients received pegylated granulocyte colony stimulating factor (PEG-G-CSF) to prevent febrile neutropenia. The most important non-hematological toxicities were grade 2 nausea and asthenia.

The PFS of patients 1 and 2 was 7 and 13 mo while patient 3 is still progression-free. Patients 1 and 2 received further therapy after cabazitaxel (abiraterone and platinum regimen) and died after 3 mo.

### DISCUSSION

BM appearance is a rare and terminal event in the natural history of PC due to greater aggressiveness and poor response to common therapies. BMs are often essentially single, supratentorial and occur with nonfocal neurological symptoms related to intracranial hypertension. A retrospective study of 103 patients with BMs showed that radiotherapy alone is an effective treatment with a median survival of 3.5 mo\(^7\).

Further improvement in survival was noted in five patients who underwent stereotactic radiosurgery (SRS). Although no complete responses were obtained, symptoms improved\(^8\).

BM s are more frequent in the CRPC setting than in the past due to the availability of new drugs and longer survival of metastatic patients. In the docetaxel era, the prognosis of patients with BMs was still poor and median survival was only 8 weeks after BM diagnosis, demonstrating the clinical ineffectiveness of docetaxel\(^9\).

Among the new approved drugs for mCRPC, such as cabazitaxel, abiraterone, enzalutamide and sipuleucel-T, only cabazitaxel has been shown to be able to pass the BBB. Cisternino and colleagues observed a non-linear accumulation of cabazitaxel in the brains of rats, occurring by saturation of the P-glycoprotein in the BBB\(^5\).

---

**Figure 1** Show a complete response in the brain lesions before and after 6 cycles of cabazitaxel. A, B: Brain metastases before cabazitaxel; C: Complete response after 6 cycles of cabazitaxel.
Table 1 Patient characteristics

|                      | Patient 1 | Patient 2 | Patient 3 |
|----------------------|-----------|-----------|-----------|
| **Age (yr)**         | 70        | 70        | 72        |
| **Comorbidities**    | Hypertension | Hypertension | Diabetes |
| **Primary treatment**| Hormonal therapy | Hormonal therapy | Surgery and radiation therapy |
| **Gleason score**    | 8 (4 + 4) | 8 (4 + 4) | 8 (5 + 3) |
| **PSA at baseline**  | 158       | 82        | 17        |
| **ADT time (mo)**    | 38        | 36        | 50        |
| **Docetaxel cycles** | 12        | 8         | 8         |
| **PSA pre-cabazitaxel** | 95     | 292       | 140       |

Sites of metastases
- Bone, lung, brain
- Bone, lung, brain
- Bone, liver, brain

Cabazitaxel cycles
- 12
- 8
- 10

Best response
- PR on brain and lung
- PR on brain and lung
- CR on liver and brain

Toxicities
- Anemia grade 1
- Nausea grade 2
- Neutropenia grade 2
- Anemia grade 2
- Neutropenia grade 2

*Before primary treatment. ADT: androgen deprivation therapy; PR: Partial response; CR: Complete response.

These 3 case reports describe the role of cabazitaxel in patients with BMs for the first time and the results are encouraging for 3 reasons.

Firstly, it shows the definite efficacy of cabazitaxel in BMs with an amazing PFS compared with the Tropic trial PFS. Secondly, the association of whole brain radiotherapy and chemotherapy with cabazitaxel gives better results in terms of radiological response and survival than the data presented above.

Thirdly, the combination does not seem to be particularly toxic, especially in terms of hematological toxicities. We administered preventive PEG-G-CSF and, as previously shown in an Italian study, it reduced the grade 3 and 4 neutropenia reported with cabazitaxel. Of note, all three patients had a gleason 8 at diagnosis, which is consistent with our previously reported findings suggesting improved PFS in patients with high gleason score receiving cabazitaxel.

Our case reports demonstrate that cabazitaxel improved PFS and overall survival in our patients with BMs and is well tolerated in combination with we decided to report these cases in a full paper without presenting them as a meeting abstract, considering that only 50% of abstracts are subsequently published as full papers. The lack of ad-hoc studies and the exclusion of men with brain metastases from phase III trials make our data the first evidence in this field. Prospective trials are needed to confirm our preliminary results.

**COMMENTS**

**Case characteristics**
All patients presented at diagnosis with a high risk disease.

**Treatment**
The authors demonstrate the efficacy of cabazitaxel on brain metastases in three castration resistant prostate cancer patients and show its profile of tolerability in combination with whole brain radiotherapy.

**Experiences and lessons**
These case reports demonstrate that cabazitaxel is highly active and well tolerated in brain metastases.

**Peer review**

Nice, well written paper with interesting data potentially useful in the clinical setting.

**REFERENCES**

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]
2. Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. *Cancer* 2012; 118: 3062-3070 [PMID: 22006014 DOI: 10.1002/cncr.26392]
3. Cafo O, Vecchia A, Fellin G, Mussari S, Russo L, Tomio L, Galligioni E. Frequency of brain metastases from prostate cancer: an 18-year single-institution experience. *Neurooncol* 2013; 111: 163-167 [PMID: 23096134 DOI: 10.1007/s11060-012-0994-1]
4. Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. *Prostate* 2014; 74: 210-216 [PMID: 24132735 DOI: 10.1002/pros.22274]
5. Cisternino S, Bourasset F, Archimbaud Y, Sémion D, Sanderink G, Scherrmann JM. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. *Br J Pharmacol* 2003; 138: 1367-1375 [PMID: 12711638 DOI: 10.1038/sj.bjp.0705150]
6. Expósito J, Jaén J, Alonso E, Tovar I. Use of palliative radiotherapy in brain and bone metastases (VARA II study). *Radiat Oncol* 2012; 7: 131 [PMID: 22863023 DOI: 10.1186/1747-471X-7-131]
7. Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK. Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience. *Cancer* 2003; 98: 363-368 [PMID: 12872258 DOI: 10.1002/cncr.11522]
8. Kim SH, Chao ST, Toms SA, Vogelbaum MA, Barnett GH, Suh JH, Weil RJ. Stereotactic radiosurgical treatment of parenchymal brain metastases from prostate adenocarcinoma. *Surg Neurol* 2008; 69: 641-646; discussion 646 [PMID: 18262258 DOI: 10.1016/j.surneu.2007.05.035]
9. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kokak I, Gravis G, Bodrogi I, Mackenzie MJ, Shn L, Roessler M, Gupta S, Sartor AO. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *Lancet* 2010; 376: 1147-1154 [PMID: 20888992 DOI: 10.1016/S0140-6736(10)61389-X]
10. Di Lorenzo G, D’Aniello C, Buonarrea C, Federico P, Rescigno P, Puglia L, Ferro M, Bosso D, Cavaliere C, Palmieri G, Sonpavde G, De Placido S. Peg-filgrastim and cabazitaxel in prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Anticaner Drugs 2013; 24: 84-89 [PMID: 23040721 DOI: 10.1097/634.0b013e32835a56bc]
11. Buonarrea CI, Pond GR, Sonpavde G, Federico P, Rescigno P, Puglia L, Bosso D, Virtuoso A, PolICASTRO T, Izzo M, Vaccaro L, Ferro M, Aiet M, Perondi S, Palmieri G, De Placido S, Di Lorenzo G. Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant pros-
Are abstracts presented at the EAU meeting followed by publication in peer-reviewed journals? A critical analysis.

Authorino R, Quarto G, Di Lorenzo G, De Sio M, Damiano

Rescigno P et al. Cabazitaxel and brain metastases
